Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients
dc.contributor.author | Suttorp, Meinolf | |
dc.contributor.author | Metzler, Markus | |
dc.contributor.author | Millot, Frederic | |
dc.contributor.author | Shimada, Hiroyuki | |
dc.contributor.author | Bansal, Deepak | |
dc.contributor.author | Kalwak, Krzysztof | |
dc.contributor.author | Sedlacek, Petr | |
dc.contributor.author | Baruchel, Andre | |
dc.contributor.author | Biondi, Andrea | |
dc.contributor.author | Hijiya, Nobuko | |
dc.contributor.author | Schultz, Kirk R. | |
dc.contributor.author | Schrappe, Martin | |
dc.contributor.buuauthor | Güneş, Adalet Meral | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Çocuk Hematoloji Kliniği. | tr_TR |
dc.contributor.researcherid | EXD-8400-2022 | tr_TR |
dc.contributor.scopusid | 24072843300 | tr_TR |
dc.date.accessioned | 2023-09-25T08:11:37Z | |
dc.date.available | 2023-09-25T08:11:37Z | |
dc.date.issued | 2018-12 | |
dc.description.abstract | Since the patent for imatinib has expired, the role of generic imatinib (GI) in the management of Philadelphia chromosome-positive (Ph+) leukemia in pediatric patients has had ongoing discussion. Some studies in adults demonstrated that equivalent doses of GI and branded imatinib (BI) result in comparable plasma concentrations and clinical efficacy. However, other studies found that GI users are more likely to stop imatinib, with intolerance and decreased persistence as the main causes. Economic factors also heavily influence GI selection. This article aims to review the present knowledge to support further discussion on the role of GI in the management of pediatric Ph+ leukemia. | en_US |
dc.identifier.citation | Suttorp, M. vd. (2018). ''Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients''. Pediatric Blood and Cancer, 65(12). | en_US |
dc.identifier.issn | 1545-5009 | |
dc.identifier.issn | 1545-5017 | |
dc.identifier.issue | 12 | tr_TR |
dc.identifier.pubmed | 30160364 | tr_TR |
dc.identifier.scopus | 2-s2.0-85052796606 | tr_TR |
dc.identifier.uri | https://doi.org/10.1002/pbc.27431 | |
dc.identifier.uri | https://onlinelibrary.wiley.com/doi/10.1002/pbc.27431 | |
dc.identifier.uri | http://hdl.handle.net/11452/34011 | |
dc.identifier.volume | 65 | tr_TR |
dc.identifier.wos | 000447556600061 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.relation.collaboration | Yurt dışı | tr_TR |
dc.relation.collaboration | Sanayi | tr_TR |
dc.relation.journal | Pediatric Blood and Cancer | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Oncology | en_US |
dc.subject | Hematology | en_US |
dc.subject | Pediatrics | en_US |
dc.subject | Generic medication | en_US |
dc.subject | Imatinib inhibitor | en_US |
dc.subject | Pediatric | en_US |
dc.subject | Ph plus leukemia | en_US |
dc.subject | Tyrosine kinase | en_US |
dc.subject | Chronic myeloid-leukemia | en_US |
dc.subject | Chronic myelogenous leukemia | en_US |
dc.subject | Follow-up | en_US |
dc.subject | Mesylate | en_US |
dc.subject | Efficacy | en_US |
dc.subject | Children | en_US |
dc.subject | Therapy | en_US |
dc.subject | Glivec | en_US |
dc.subject | Safety | en_US |
dc.subject | Tablet | en_US |
dc.subject.emtree | Generic drug | en_US |
dc.subject.emtree | Imatinib | en_US |
dc.subject.emtree | Antineoplastic agent | en_US |
dc.subject.emtree | Generic drug | en_US |
dc.subject.emtree | Imatinib | en_US |
dc.subject.emtree | Protein kinase inhibitor | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Cancer chemotherapy | en_US |
dc.subject.emtree | Cancer patient | en_US |
dc.subject.emtree | Child | en_US |
dc.subject.emtree | Childhood leukemia | en_US |
dc.subject.emtree | Comparative study | en_US |
dc.subject.emtree | Hrug efficacy | en_US |
dc.subject.emtree | Hrug formulation | en_US |
dc.subject.emtree | Health care organization | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Patient advocacy | en_US |
dc.subject.emtree | Pediatric patient | en_US |
dc.subject.emtree | Pharmacological parameters | en_US |
dc.subject.emtree | Philadelphia chromosome positive cell | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Chronic myeloid leukemia | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.mesh | Antineoplastic agents | en_US |
dc.subject.mesh | Child | en_US |
dc.subject.mesh | Drugs, generic | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Imatinib mesylate | en_US |
dc.subject.mesh | Leukemia, myelogenous, chronic, BCR-ABL positive | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Protein kinase inhibitors | en_US |
dc.subject.scopus | Imatinib; Chronic Myeloid Leukemia; Generic Drug | en_US |
dc.subject.wos | Oncology | en_US |
dc.subject.wos | Hematology | en_US |
dc.subject.wos | Pediatrics | en_US |
dc.title | Generic formulations of imatinib for treatment of Philadelphia chromosome-positive leukemia in pediatric patients | en_US |
dc.type | Article | |
dc.wos.quartile | Q3 | en_US |
dc.wos.quartile | Q1 (Pediatrics) | en_US |
Files
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: